| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JNC.13297 |
| P8608 | Fatcat ID | release_ef7lvyzdzvfptcwi57drt42uou |
| P698 | PubMed publication ID | 26332787 |
| P50 | author | Kaj Blennow | Q28321550 |
| Henrik Zetterberg | Q6252048 | ||
| Johannes Streffer | Q57587710 | ||
| Marc Mercken | Q117234565 | ||
| J Randall Slemmon | Q117234589 | ||
| P2093 | author name string | Niels Andreasen | |
| Alice Shapiro | |||
| Gary Romano | |||
| P2860 | cites work | “Mini-mental state” | Q25938989 |
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| Amyloid precursor protein trafficking, processing, and function | Q29617429 | ||
| Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system | Q33262322 | ||
| Vascular pathology in the aged human brain | Q33699436 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography | Q34435040 | ||
| Apolipoprotein E: From lipid transport to neurobiology | Q34497951 | ||
| Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study | Q35669559 | ||
| Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints | Q36661066 | ||
| The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers | Q37008887 | ||
| Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta | Q37304821 | ||
| Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure | Q37307244 | ||
| Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives | Q37769104 | ||
| Regulated intramembrane proteolysis--lessons from amyloid precursor protein processing | Q37854085 | ||
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
| Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid | Q42218996 | ||
| Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease | Q44282867 | ||
| Enrichment and analysis of Alzheimer's Abeta1-42 peptide in human plasma and whole blood. | Q45972670 | ||
| CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. | Q46092918 | ||
| APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. | Q47376522 | ||
| Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases | Q48260033 | ||
| Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition | Q48475140 | ||
| Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. | Q51576488 | ||
| Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. | Q51723038 | ||
| Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. | Q51905659 | ||
| Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. | Q51924516 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| Differential CSF biomarker levels in APOE-epsilon4-positive and -negative patients with memory impairment. | Q52001000 | ||
| Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. | Q53412673 | ||
| Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects. | Q53430179 | ||
| No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression | Q57676222 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| cerebrospinal fluid | Q54196 | ||
| P304 | page(s) | 1049-1058 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio. | |
| P478 | volume | 135 |
| Q51737722 | Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. |
| Q39451611 | Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies |
| Q54943546 | Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. |
| Q37664735 | BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants |
| Q39195180 | Dynamic Nature of presenilin1/γ-Secretase: Implication for Alzheimer's Disease Pathogenesis. |
| Q93066085 | Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta |
| Q33871427 | Multicenter Analytical Validation of Aβ40 Immunoassays. |
| Q41097447 | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts |
| Q59802837 | Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays |
Search more.